louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00722306: A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers
Official title: A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Insomnia
Keywords: non-restorative
sleep
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-07-25
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine the mass balance of PD 0200390


Eligibility criteria: Inclusion Criteria:

* Healthy

Exclusion Criteria:

* unhealthy, or concomitant meds

Primary outcomes:
measure: Radioactivity parameters in plasma and whole blood - Cmax , Tmax , AUCinf, AUClast, t1/2, CL/F and V/F and Total 14C data in blood, urine and feces
timeFrame: 2 days
Secondary outcomes:
measure: % urinary recovery
timeFrame: 2 days
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Pfizer Investigational Site
state: Connecticut
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00397306: Evaluation of a Bioimpedance Method for Determination of Dry Weight in Dialysis Patients
Official title: Study for the Evaluation of a Bioimpedance Method for Determination of Dry Weight in Dialysis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Renal Insufficiency, Chronic
Lead sponsor: University Hospital, Saarland
Sponsor class: OTHER
First posted: 2006-11-09
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is the evaluation of a bioimpedance method for determination of dry weight in dialysis patients. Additionally normal tissue hydration in non-Dialysis patients is investigated in healthy subjects and patients with chronic kidney disease in stages K/DIGO I-IV


Eligibility criteria: Inclusion Criteria:

* clinically stable on dialysis within the last three months
* signed written informed consent

Exclusion Criteria:

* acute myocardial infarction or stroke within the last six months
* heart failure stage NYHA IV
* concommitant participation in other interventional trials
* psychiatric conditions that prevent subject from following the study procedures / protocol
* pregnancy or lactation
* limb amputation
* cardiac pacemaker
* joint implants
* implantable pumps and other metallic implants

For healthy subjects and CKD patients in stages K/DIGO I-IV the above mentioned criteria other than the first mentioned are applicable respectively.

Primary outcomes:
measure: Bioimpedance Dry weight
Secondary outcomes:
measure: Resistance
measure: Resistivity
measure: Blood pressure
measure: LV Diameter
measure: Shortening Fraction
measure: Wall thickness LA, LV
measure: Quality of Life
measure: EPO-Dose
Other outcomes:
Locations:
city: Homburg
country: Germany
facility: University Hospital of Saarland, Dept. of Internal Medicine IV, Div. of Nephrology and Hypertension
state: Saarland
Study officials:
affiliation: University Hospital of Saarland, Department of Internal Medicine IV, Division of Nephrology and Hypertension
name: Eric Seibert, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00412906: Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls
Official title: Study of Gene Expression in Fat and Muscle Tissue in Type 2 Diabetics and Healthy Controls During Experimental Endotoxemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Type 2 Diabetes
Endotoxemia
Keywords: Low-grade inflammation
insulin resistance
Metabolism
Type 2 diabetes
Endotoxemia
Fat tissue
Muscle tissue
RT-PCR
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2006-12-19
Enrollment: 48
Sex: MALE
Minimum age (years): 25
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The aim of the present protocol is to study gene activity in fat and muscle tissue in type 2 diabetics and healthy volunteers after injection of E. coli endotoxin.We hereby hope to gain insight in some mechanisms behind the association between inflammation and insulin resistance.

Detailed description: Numerous studies have shown an association between low-grade inflammation and insulin-resistance in type 2 diabetics. It is also well-known that septic patients often develop insulin-resistance. The pathogenetic mechanisms behind the association between inflammation and insulin-resistance is not fully understood.

In this study we create an experimental inflammation by giving E. coli endotoxin 0,3 ng/kg iv to type 2 diabetics and healthy controls. Muscle biopsies are taken at 0, 2, 4 and 6 hours after injection, while fat biopsies are taken 0, 2, 4, 6 and 8 hours after endotoxin. mRNA for adiponectin, leptin, PPAR-gamma, PGC-1, PAI-1 and cytokines in tissue is later measured by RT-PCR.

Blood samples are drawn on an hourly basis until 8 hours after endotoxin injection for common biochemical analyses including white blood cell count. Plasma is spared and later analyzed for cytokines, PAI-1 and VCAM-1/ICAM-1.

Eligibility criteria: Inclusion Criteria:

* Healthy
* Type 2 diabetes

Exclusion Criteria:

* Heart failure
* Lung disease
* Anti-coagulation treatment

Primary outcomes:
measure: Gene expression evaluated by measuring mRNA via RT-PCR. Plasma cytokine content, PLasma PAI-1 content, endotoxemia score
Secondary outcomes:
measure: Mean Arterial Pressure, heart rate, Temperature,
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Centre of Inflammaiton and Metabolism, Rigshospitalet
Study officials:
affiliation: Rogshospitalet, Denmark
name: Anne Sofie Andreasen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Andreasen AS, Kelly M, Berg RM, Moller K, Pedersen BK. Type 2 diabetes is associated with altered NF-kappaB DNA binding activity, JNK phosphorylation, and AMPK phosphorylation in skeletal muscle after LPS. PLoS One. 2011;6(9):e23999. doi: 10.1371/journal.pone.0023999. Epub 2011 Sep 13.
Clinical trial NCT04853706: Validation of the 3D-CAM Turkish Version
Official title: Validation of the 3D-CAM Turkish Version in Surgical ICU Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Delirium
Validity
Lead sponsor: Aydin Adnan Menderes University
Sponsor class: OTHER
First posted: 2021-04-21
Enrollment: 245
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: 3D CAM into Turkish validity and reliability on postoperative delirium will be test as a prospective diagnostic study. After approval by Dr. Edward R. Marcantonio, (15) will translation and back-translation. The original 3D-CAM will translate into Turkish by two medical doctor .The two translational versions will be discussed and merged into a final version. Back translation will performed in regardless of any information from its original version by another two medical doctor. Both the translated and back translated versions will sent to Dr. Marcantonio for approval. Eligibility and the documentation of consent will be confirmed at the preoperative visit. During this visit, patients will provide demographic and historical medical information, including information regarding medication usage. The Mini-Mental State Exam (MMSE) will be performed.

Delirium assessment

Delirium assessment with the 3D-CAM Before the study period, all researchers will participate online training program on 3D CAM. Delirium will be evaluated using the 3D CAM every each morning and evening (18:00-20:00) for postoperative 3 days.

Delirium assessment with the DSM-5 The psychiatrist investigator who was blinded to the 3D-CAM assessment results, will evaluate the patients according to the criteria of DSM-5 within 3 min after the 3D-CAM assessment.


Eligibility criteria: Inclusion Criteria:

* 18 years and older
* ASA Physical Status 1-3
* Admitted to the ICU after surgery with a predicted length of stay for more than 48 h
* MMSE ≥ 20 (to exclude dementia)

Exclusion Criteria:

* Refused to participate
* Patients with severe visual or auditory disorder/handicaps or endotracheal intubation which might impede communication
* Presence of a major psychiatric condition such as bipolar disorder, major depression, schizophrenia, Alzheimer or dementia, Parkinsonism
* Deep sedation or coma
* ASA physical status IV or V

Primary outcomes:
measure: Assessment of delirium
timeFrame: 3 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Mu DL, Ding PP, Zhou SZ, Liu MJ, Sun XY, Li XY, Wang DX. Cross-cultural adaptation and validation of the 3D-CAM Chinese version in surgical ICU patients. BMC Psychiatry. 2020 Mar 24;20(1):133. doi: 10.1186/s12888-020-02544-w.
Clinical trial NCT01632306: A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Official title: Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Pancreatic Cancer
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
Collaborators: name: Mayo Clinic
First posted: 2012-07-02
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.


Eligibility criteria: Inclusion Criteria:

* Metastatic pancreatic cancer with metastases amenable to biopsy
* Willingness to provide tissue and blood samples for research purposes
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

Exclusion Criteria:

* History of islet cell, acinar cell, or cystadenocarcinomas
* Prior cytotoxic chemotherapy for metastatic disease, except prior gemcitabine or FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin)
* Radiation therapy, immunotherapy or biologic therapy \<28 days prior to study entry

Primary outcomes:
measure: Change From Baseline to 4 Hours Post-Treatment on Day 0 in Glycogen Synthase Phosphorylation
timeFrame: Baseline, 4 Hours Post-Treatment on Day 0
Secondary outcomes:
measure: Overall Survival (OS)
timeFrame: Baseline to Date of Death Due to any Cause Up to 21 Months
measure: Percentage of Participants Who Survived at 6 Months
timeFrame: Baseline to Date of Death to any cause Up to 6 Months
measure: Progression Free Survival (PFS)
timeFrame: Baseline to Disease Progression Up to 18 Months
measure: Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
timeFrame: Baseline Up to 6 Months
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic of Jacksonville
state: Florida
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT04969406: A Prospective Trial of the Intelon BOSS(TM) System
Official title: A Prospective Trial Designed to Evaluate the Repeatability and Reproducibility of the Intelon BOSS(TM) System
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Cornea
Lens Diseases
Lead sponsor: Intelon Optics, Inc
Sponsor class: INDUSTRY
First posted: 2021-07-20
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: A prospective, open-label, single-site clinical trial designed to evaluate the repeatability and reproducibility of biomechanical imaging by the BOSS device. Subjects will undergo unilateral biomechanical mapping of the cornea and lens by three BOSS devices operated by three (3) different operators.


Eligibility criteria: Inclusion Criteria:

1. Age 18 years or older
2. Availability, willingness and sufficient cognitive awareness to comply with the examination procedures and schedule
3. Signed Written Informed Consent

Exclusion Criteria:

1. No light perception or low vision rendering the subject unable to fixate to keep gaze still enough to acquire images
2. Presence of corneal opacity
3. Presence of cortical cataracts visible in an undilated pupil
4. Any systemic disease or disorder which would prohibit image acquisition (e.g., Parkinson's Disease).

Primary outcomes:
measure: Analysis of variance in corneal and lens measurements to determine repeatability and reproducibility
timeFrame: Evaluation Visit (within 30 days of the Screening Visit)
Secondary outcomes:
Other outcomes:
Locations:
city: Fayetteville
country: United States
facility: Vold Vision plc
state: Arkansas
Study officials:
References:
Clinical trial NCT01178606: Measurement of Echogenic Area in the Border of the Fetal Ventricles
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Healthy
Keywords: echogenic halo around lateral fetal ventricles
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2010-08-10
Enrollment: 0
Sex: ALL
Minimum age (years): 22
Maximum age (years): 37
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Sampling method: PROBABILITY_SAMPLE
Study population: pregnant women 22-37GA, singleton normal pregnancy

Brief summary: Sonographic coronal section in the lateral fetal ventricles shows echogenic area in the ventricles borders creating an "halo" around the ventricles. Histologically this area correlates to the Stratified transitional field. In this study we would like to measure this area for the purpose of creating a nomogram.


Eligibility criteria: Inclusion Criteria:

* pregnant women 22-37 GA
* well dated pregnancy
* singleton pregnancy

Exclusion Criteria:

* no first trimester dating
* multifetal pregnancy
* known CNS abnormalities in the fetus
* small for gestational age

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: Meir Medical Center
Study officials:
References:
Clinical trial NCT05537506: Evaluation of Effects of Bracket's Slot System on the Quantity and Quality of Teeth Movements During Orthodontic Leveling and Alignment Stage
Official title: Evaluation of Effects of Bracket's Slot System on the Quantity and Quality of Teeth Movements During Orthodontic Leveling and Alignment Stage : A Prospective Clinical Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Moderate and Severe Crowding in Lower Dental Arch
Keywords: Slot 0.018
Slot 0.022
Bracket
Leveling
Alignment
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2022-09-13
Enrollment: 24
Sex: ALL
Minimum age (years): 14
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of effect of bracket slot system on the quality and quantity of tooth movement during leveling and alignment stage


Eligibility criteria: Inclusion Criteria:

* An age range from14 to18 years. All permanent teeth are erupted(3rd molar not included).
* Angle class I malocclusion with normal facial proportions.
* Moderate to severe crowding in the lower dental arch asassessed by lett irregularity Index that require treatment with fixed appliance using extraction approach.
* There is no previous orthodontic treatment.

Exclusion Criteria:

* Poor oral hygiene or periodontally compromised teeth.
* Craniofacial anomalies or previous history of trauma, bruxism, or Parafunctions.
* Uncooperativepatient.

Primary outcomes:
measure: Rate of tooth movement by different bracket slot system
timeFrame: At 8 months
Secondary outcomes:
Other outcomes:
Locations:
city: Naşr
country: Egypt
facility: Alazhar university
state: Cairo
Study officials:
affiliation: Al-Azhar University
name: Alazhar University
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mavragani M, Vergari A, Selliseth NJ, Boe OE, Wisth PL. A radiographic comparison of apical root resorption after orthodontic treatment with a standard edgewise and a straight-wire edgewise technique. Eur J Orthod. 2000 Dec;22(6):665-74. doi: 10.1093/ejo/22.6.665.
Clinical trial NCT00406406: Study Evaluating SKI-606 Administered to Healthy Subjects
Official title: Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SKI-606 Administered Orally to Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2006-12-04
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Safety and tolerability of SKI-606 in healthy subjects; the influence of food intake on the same.


Eligibility criteria: Inclusion Criteria:

* Healthy

Primary outcomes:
measure: Pharmacokinetics; safety and tolerability; influence of food.
Secondary outcomes:
Other outcomes:
Locations:
city: Utrecht
country: Netherlands
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
affiliation: For Netherlands, trials-NL@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02255006: Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion Injury
Official title: Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion Injury Via Adenosine Triphosphate-sensitive Potassium Channels or Prostaglandin Pathway
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Healthy
Keywords: volunteer
BMI(25 kg/m2)
Lead sponsor: Kyunghee University Medical Center
Sponsor class: OTHER
Collaborators: name: Ministry of Health & Welfare, Korea
First posted: 2014-10-02
Enrollment: 36
Sex: ALL
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Some studies suggest that acupuncture improve flow mediated dilation (FMD) that represents endothelial function, but no study has investigated whether acupuncture protects against ischemia and reperfusion (IR)-induced endothelial dysfunction in humans.

This is a prospective crossover study clinical trial. In the first crossover study, 20 healthy nonsmoking volunteers (25 to 40 years old) will be randomly assigned to acupuncture or control. Endothelium-dependent, FMD of the brachial artery will be measured before and after IR (15 minutes of ischemia at the level of the proximal upper arm followed by 15 minutes of reperfusion). Acupuncture will be performed from 10 minute after ischemia till the end time of reperfusion for 20 minutes. In the second single arm study, 16 volunteers are administered oral 5mg glibenclamide two hours before IR injury (n=8) or selective cox-2 inhibitor celecoxib 200mg twice a day for 5 days to know what mechanism is responsible for acupuncture effect on IR injury. FMD measurements and acupuncture intervention during IR injury are same as above mentioned.


Eligibility criteria: Inclusion Criteria:

* healthy volunteer age 25 to 40 years
* non-smoker

Exclusion Criteria:

* hypertension (\>140/90 mmHg), diabetes any cardiovascular disease kidney disease thyroid disease cerebrovascular disease liver disease (bilirubin level \>2 mg/dl) pregnancy body mass index \>25 kg/m2

Primary outcomes:
measure: The difference of endothelial function
timeFrame: 4 week
Secondary outcomes:
measure: The difference of endothelial function
timeFrame: 4 week
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Kyung Hee University Medical Center
Study officials:
affiliation: Kyunghee University Medical Center
name: Weon Kim
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01719406: The OHSU Pregnancy Exercise & Nutrition (PEN) Program
Official title: Randomized Control Pilot of a Behavior-based Exercise and Diet Intervention to Reduce Risk Factors for Gestational Diabetes Among Otherwise Healthy Pregnant Women.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gestational Diabetes
Keywords: Gestational diabetes
Exercise
Diet
Fruits
Vegetables
Whole grains
pregnancy weight
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
First posted: 2012-11-01
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Personal behaviors can influence development of Gestational Diabetes Mellitus (GDM), a condition that can adversely affect the pregnant woman, her developing fetus and future events for both. To reduce GDM risk, we will develop and implement an in-person team and web-based nutrition and exercise program for women, beginning in their first trimester. A scripted, peer-led, 20-week educational program, tailored for pregnant women working in teams (5 women/team), will be developed and implemented among pregnant employees and/or their spouses. Each weekly thirty minute session will focus on achieving 30-minutes of moderate daily physical activity with nutrition targets of five servings of fruits and vegetables, 3 servings of whole grains and lower fat food choices. Diet, exercise and lab assessments will occur before enrollment during the first trimester, each subsequent trimester and 12 weeks after delivery. In addition to exercise and diet survey results, we will assess fasting glucose, insulin, hemoglobin A1C levels, pregnancy weight gain, blood pressure, lipid and lipoprotein levels, pedometer records, weekly accelerometer data, each trimester and at 12 weeks post delivery, as well as gestational birth age, Apgar score, delivery mode and infant birth weight, and weekly health thermometer self-ratings during the assessment period.


Eligibility criteria: Inclusion Criteria: Healthy first trimester pregnant women -

Exclusion Criteria: hypertension, diabetes, known cardiopulmonary disease; orthopedic problems or other conditions that would prevent regular physical activity.

-

Primary outcomes:
measure: Achieving 30 minutes of daily exercise, four or more times each week
timeFrame: 32 weeks
Secondary outcomes:
measure: Eating 5 or more servings of vegetables and/or fruits each day
timeFrame: 32 weeks of the study
Other outcomes:
measure: Pregnancy weight gain
timeFrame: 20 weeks
measure: HemoglobinA1C
timeFrame: Each trimester and 12-weeks post delivery
Locations:
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
Study officials:
References: